Filing Flows

Filing Flows › 8-K events › Supernus Pharmaceuticals

Supernus Pharmaceuticals: change in control

Form 8-K filed Nov 2, 2026 · items 1.01, 2.01, 2.03, 3.03, 5.01, 5.03, 7.01

Changes in controlSupernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

What the filing says

At the Effective Time, pursuant to the terms of the Merger Agreement and the certificate of merger filed with the Secretary of State of the State of Delaware, the certificate of incorporation of the Company, as in effect immediately prior to the Effective Time, was amended and restated in its entirety. A copy of the am

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.01: +0.1% next session across 2,671. Item 2.03: 0.0% next session across 13,268. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Item 5.01 — Change in control. A change in control: someone now controls the company.

Supernus Pharmaceuticals at a glance

Latest quarterQ3 2026
Revenue$226.8M
Revenue Y/Y+18%
Operating margin9.3%
IndustryPharmaceutical Preparations

Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%. The chart follows the revenue to costs, profit and cash.

Supernus Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Supernus Pharmaceuticals’s other material 8-Ks

Other recent changes in control

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.